Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Tetraphase Pharmaceuticals (TTPH) Share Price
Headlines about Tetraphase Pharmaceuticals (NASDAQ:TTPH) have trended somewhat positive on Saturday, according to Accern. Accern identifies positive and negative press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Tetraphase Pharmaceuticals earned a news impact score of 0.12 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 44.9871544869114 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
These are some of the media stories that may have effected Accern’s scoring:
- SunTrust Banks Comments on Tetraphase Pharmaceuticals Inc’s FY2017 Earnings (TTPH) (americanbankingnews.com)
- Tetraphase Pharmaceuticals Inc (TTPH) Forecasted to Earn FY2017 Earnings of ($2.80) Per Share (americanbankingnews.com)
- Tetraphase Pharmaceuticals Inc Expected to Post FY2022 Earnings of $0.58 Per Share (TTPH) (americanbankingnews.com)
- H.C. Wainwright Slashes Price Target for Tetraphase Pharmaceuticals Inc (TTPH); Here’s Why (smarteranalyst.com)
- Here's Why Tetraphase Pharmaceuticals Crashed 60.4% Today (finance.yahoo.com)
Shares of Tetraphase Pharmaceuticals (TTPH) traded down $0.08 during mid-day trading on Friday, reaching $2.12. The company’s stock had a trading volume of 1,909,900 shares, compared to its average volume of 1,467,164. The stock has a market cap of $113.51, a price-to-earnings ratio of -0.74 and a beta of 2.29. Tetraphase Pharmaceuticals has a 12 month low of $2.10 and a 12 month high of $9.93.
In other news, Director L Patrick Gage acquired 3,880 shares of the firm’s stock in a transaction on Wednesday, November 29th. The shares were bought at an average price of $6.45 per share, for a total transaction of $25,026.00. Following the acquisition, the director now owns 38,880 shares of the company’s stock, valued at approximately $250,776. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Jacques Dumas sold 8,750 shares of the firm’s stock in a transaction on Tuesday, January 30th. The shares were sold at an average price of $6.22, for a total value of $54,425.00. Following the completion of the transaction, the insider now owns 8,750 shares in the company, valued at approximately $54,425. The disclosure for this sale can be found here. Company insiders own 5.50% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This piece was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another domain, it was stolen and reposted in violation of international trademark & copyright laws. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2018/02/17/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-tetraphase-pharmaceuticals-ttph-share-price.html.
About Tetraphase Pharmaceuticals
Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.
Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.